CNY256.68
1.05% today
Shanghai, Jun 25, 09:00 am CET
ISIN
CH1391448177
Symbol
688235
Sector
Industry

BeOne Medicines Stock price

CNY256.68
+28.35 12.42% 1M
+96.68 60.43% 6M
+95.66 59.41% YTD
+135.68 112.13% 1Y
+153.68 149.20% 3Y
+95.70 59.45% 5Y
+95.70 59.45% 10Y
+95.70 59.45% 20Y
Shanghai, Closing price Wed, Jun 25 2025
+2.66 1.05%
ISIN
CH1391448177
Symbol
688235
Sector
Industry

Key metrics

Basic
Market capitalization
CNY221.5b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
Valuation (TTM | estimate)
P/E
-108.56 | 289.42
P/S
7.41 | 6.02
EV/Sales
- | -
EV/FCF
-
P/B
-
Margin (TTM | estimate)
Gross
84.66%
EBITDA
- | 5.77%
EBIT
-7.50%
Net
-10.58% | -
Free Cash Flow
-5.45%
Financials (TTM | estimate)
Revenue
CNY29.9b | CNY36.8b
EBITDA
- | CNY2.1b
EBIT
CNY-2.2b
Net Income
CNY-3.2b | -
Free Cash Flow
CNY-1.6b
Growth (TTM | estimate)
Revenue
51.66% | 35.12%
EBITDA
- | 158.05%
EBIT
72.42%
Net Income
48.77% | -
Free Cash Flow
85.25%
Financial Health
Equity Ratio
56.44%
Return on Equity
-20.59%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
CNY-2.34
FCF per Share
Short interest
-
Employees
11.00k
Rev per Employee
CNY2.47
Show more

Is BeOne Medicines a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,894 stocks worldwide.

BeOne Medicines Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a BeOne Medicines forecast:

29x Buy
97%
1x Hold
3%

Analyst Opinions

30 Analysts have issued a BeOne Medicines forecast:

Buy
97%
Hold
3%

Financial data from BeOne Medicines

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
29,902 29,902
52% 52%
100%
- Direct Costs 4,588 4,588
47% 47%
15%
25,315 25,315
53% 53%
85%
- Selling and Administrative Expenses 13,377 13,377
16% 16%
45%
- Research and Development Expense 14,285 14,285
7% 7%
48%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -2,244 -2,244
72% 72%
-8%
Net Profit -3,165 -3,165
49% 49%
-11%

In millions CNY.

Don't miss a Thing! We will send you all news about BeOne Medicines directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Beigene Ltd is a KY-based company operating in Biotechnology industry. BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The firm has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The firm has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. The company also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

Head office Cayman Islands
Employees 11,000
Website www.beigene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today